You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775

Citation Tools

Article menu

Download PDFPDF

Oral Abstracts
Awards Ceremony & Plenary 4: Seminal Abstract Presentations
O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Makker V, Colombo N, Casado Herráez A, et al
O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775
International Journal of Gynecologic Cancer 2021;31:A4-A5.